Retatrutide and Knee Osteoarthritis: What the Phase 3 Trials Found
Published · Page updated
Bookmark this page
Save this article in your browser so you can find it again:
- Computer: Press Ctrl+D (Windows) or ⌘+D (Mac).
- iPhone or iPad: In Safari, tap Share, then Add Bookmark.
- Android: In Chrome, open the menu and tap the star.
Other browsers may use a different menu.
Retatrutide knee osteoarthritis research has produced encouraging phase 3 results, but pain relief, weight change and joint repair remain different claims. Understanding the new findings means looking at the comparison with placebo, the people enrolled and the safety results alongside the headline.
This guide examines the November 8, 2026 journal report and related primary research materials. It explains what the results support and which questions remain open.
Publisher disclosure: Bio Research LLC operates Bio Peptides Labs and sells retatrutide-labeled research materials. This is commercially interested, AI-assisted editorial content, not an independent scientific review. Sources were checked November 10, 2026. Access included the indexed journal abstract, public trial records, conference material and institutional reporting; the complete journal paper, supplement and participant-level data were not independently reviewed.

What did the retatrutide knee osteoarthritis studies examine?
Retatrutide is an investigational molecule acting at GIP, GLP-1 and glucagon receptors. It is often discussed with GLP-1 medicines, but receptor activity alone does not establish a clinical benefit. Lilly's molecule and development overview.
TRIUMPH-4 and the knee-osteoarthritis group within TRIUMPH-1 compared retatrutide with placebo in adults without diabetes who had painful knee osteoarthritis and a body-mass index of at least 27. The two trial records describe the eligibility and planned measurements. The knee-OA group should not be confused with the entire broader TRIUMPH-1 population. TRIUMPH-4 registry, TRIUMPH-1 registry.
This matters when applying a headline to a different person or condition. A finding in painful knee OA with overweight or obesity does not automatically extend to every cause of knee pain, other joints or people outside the enrolled population.
How much did knee pain and body weight change?
The journal's pain results are average decreases on the 0–10 WOMAC pain scale, using its hybrid-treatment analysis. Ranges below span the tested retatrutide groups; they are not confidence intervals or individual response ranges.
Trial | Participants | Follow-up | Retatrutide pain-score decrease | Placebo decrease |
|---|---|---|---|---|
TRIUMPH-4 | 445 | 68 weeks | 3.74–3.96 points | 2.12 points |
TRIUMPH-1-OA | 574 | 80 weeks | 3.22–3.64 points | 1.87 points |
In TRIUMPH-4, average weight reduction was 20.0%–23.7% across retatrutide groups versus 4.6% with placebo under the treatment-policy analysis. Lilly funded the trials. Original journal abstract and publication record.
The placebo column is essential. A group's total improvement is different from its additional improvement relative to the comparison group. Neither number promises the result an individual would experience. The journal abstract reports that, relative to placebo, mean pain scores decreased by an additional 1.61–1.83 points in TRIUMPH-4 and 1.35–1.77 points in TRIUMPH-1-OA across the reported retatrutide groups. These differences use the pain analysis described above and are not individual response predictions. Indexed journal abstract.
Why do different reports show different percentages?
An analysis must decide how to handle events such as stopping or changing treatment. An estimand names the effect the analysis aims to estimate, including those decisions. Missing observations also need an explicit analysis approach. ICH guidance on estimands and analysis.
For example, the TRIUMPH-4 conference abstract reports efficacy-estimand findings, while the table above follows the journal's labeled pain analysis. These should not be mixed into one result or treated as separate confirmatory trials. Original TRIUMPH-4 conference abstract.
A second distinction concerns percentages themselves. A mean percentage reduction in pain is different from the percentage of people meeting a response threshold. Neither is the percentage whose disease has been cured.
Northwestern University's summary reports that, in a pooled analysis, about two-thirds of retatrutide recipients had at least a 50% reduction in knee pain, compared with 38% receiving placebo. That describes a threshold response, not freedom from pain. We attribute this figure to the university summary; its complete pooled-analysis details were not available in the journal abstract we reviewed. Northwestern report.
Our guide to reading peptide studies explains why the endpoint and comparison should stay attached to every number.
What did the safety findings show?
The journal abstract identifies gastrointestinal events as the most common adverse events and reports more serious adverse events overall with retatrutide in both trials. Original trial report.
The public TRIUMPH-4 conference safety table gives additional context: serious adverse events occurred in 9.5%–10.8% of the retatrutide safety groups versus 2.0% with placebo. Adverse events leading to treatment discontinuation occurred in 12.9%–18.2% versus 4.0%, respectively. These percentages describe that trial's safety population. Original conference safety table.
The TRIUMPH-1-OA safety table shows variation among treatment groups, so an overall summary should not imply that every retatrutide group had a higher event rate than placebo. Original TRIUMPH-1-OA safety table.
An adverse event occurs during observation; that fact alone does not establish that the medicine caused it. At the same time, favorable efficacy results do not make safety differences irrelevant. Interpretation requires the event types, severity, withdrawals and longer follow-up, not simply a statement that side effects were “manageable.”
Does less knee pain mean cartilage repair or fewer replacements?
The reviewed reports do not establish cartilage repair, reversal of osteoarthritis or prevention of knee replacement. Northwestern identifies disease progression, replacement risk and effects in people without overweight as questions needing further investigation. It also describes uncertainty about how much benefit might involve reduced joint loading versus other mechanisms. Institutional discussion of remaining questions.
A symptom score, a structural measurement and a surgical outcome answer different questions. Structural endpoints appearing in a study plan do not establish a favorable structural result. Similarly, weight loss occurring alongside pain relief does not by itself quantify an effect independent of weight change.
Useful next research questions include:
How durable are pain and function changes after treatment ends?
What do longer-term structural assessments show, and do those changes matter to patients?
Can a study establish a change in the need for joint replacement?
How do benefits and harms differ across clearly defined patient groups?
What happens to strength, mobility and body composition during substantial weight change?
These are research priorities, not findings already demonstrated by these trials.
Is retatrutide approved for knee osteoarthritis?
As checked November 19, 2026, FDA states that retatrutide is not a component of an FDA-approved drug and has not been established as safe and effective for any condition. A positive phase 3 publication is not a regulatory approval. FDA's current retatrutide notice.
The trial findings also do not establish that a laboratory research vial is equivalent to the study formulation. This article provides no dosing or administration guidance and does not recommend changing an osteoarthritis care plan.
Is this evidence that retatrutide is better than semaglutide or tirzepatide for knee OA?
These two OA trials used placebo comparisons. They do not establish superiority over either medicine for knee osteoarthritis. Comparing percentages from different studies cannot replace an appropriate direct comparison.
Our retatrutide, tirzepatide and semaglutide research guide separates molecules, populations and endpoints. That context helps readers interpret new results without treating every study as a ranking of treatments.
Review method and source access
This focused educational review follows the original journal abstract, trial registries, public conference abstracts and safety tables, Northwestern's summary, and FDA/Lilly status information. Direct access to the complete NEJM paper and supplement was unavailable; no full-text or individual-data review is claimed. Conference and journal reports of the same trials were not counted as independent evidence. This is not a systematic review or an individualized medical assessment.
For citation corrections, use our editorial contact.
References
On November 19, 2026, we rechecked the indexed journal abstract, the two registry records and FDA's retatrutide statement. Conference tables and the university summary retain their November 10 review scope. We did not independently review the full journal paper, supplement or individual-level data.
